Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First patients sought for groundbreaking brain cancer drug trial

NCT ID NCT07185880

Summary

This is the first-ever study in people to test the safety and best dose of a new drug called MT-125 for glioblastoma, a fast-growing brain tumor. The drug is designed to be taken alongside standard radiation therapy to try to make the radiation work better. The study will enroll up to 36 adults with a newly diagnosed, specific type of glioblastoma that does not respond well to standard chemotherapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic

    Phoenix, Arizona, 85054, United States

    Contact

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

    Contact

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

    Contact

Conditions

Explore the condition pages connected to this study.